Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Gets CDC Contract to Develop Flu Tests

NEW YORK (GenomeWeb News) – Nanogen said today that it has been awarded a two-year, $10.4 million contract from the US Centers for Disease Control and Prevention to develop multi-analyte molecular diagnostic tests for influenza.
 
Under the contract, San Diego-based Nanogen will develop a rapid molecular test that simultaneously detects and differentiates influenza type A and type B, seasonal flu (H1N1 and H3N2) strains, and respiratory syncytial virus. The firm also will develop a secondary test for avian flu strains including H5N1, H7N1, and H9N1, to be available for samples testing positive for flu A but negative for seasonal flu.
 
Nanogen said it would develop the tests in combination with the Medical College of Wisconsin and HandyLab, and it expects the tests to be more sensitive and quicker than currently available molecular diagnostic assays for flu. Nanogen said that the proposal presented to the CDC said that it would use its MGB probe technology in combination with HandyLab’s Raider instrument, a microfluidic real-time PCR-based system.
 
Nanogen also is developing a rapid, point-of-care flu test for the CDC, under a contract signed in December 2006.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.